What’s On: Lung Cancer Awareness Month 2025

Lung cancer is still the leading cause of cancer-related death in Canada. About 1 in 14 Canadians will be diagnosed with lung cancer at some point in our lives.

While the statistics are sobering, Lung Cancer Awareness Month is about so much more than statistics.

New Treatment Option Moving Towards Reimbursement for Adults with Operable Early-Stage NSCLC

New Treatment Option Moving Towards Reimbursement for Adults with Operable Early-Stage NSCLC

Pembrolizumab (Keytruda) is one step closer to being funded via Canada’s various provincial drug plans for the treatment of adults with operable stage II, IIIA, or IIIB (T3 to 4N2) non-small cell lung cancer (NSCLC) to be used with chemotherapy before surgery to shrink the cancer and then used on its own after surgery to help keep the cancer from coming back, if certain conditions are met.